Scholarlink

Background <p>Hypertension is a leading cause of cardiovascular and cerebrovascular disease-related morbidity and mortality. This study aimed to investigate the prevalence, treatment rate and control rate of hypertension among Chinese adults from 2019 to the present through a meta-analysis, providing evidence for the development of strategies and measures for hypertension prevention and control at the national level.</p> Methods <p>We systematically searched PubMed, Embase, The Cochrane Library, CNKI, Wanfang and VIP to identify cross-sectional studies published from 2019 onwards that reported the prevalence, treatment rate and control rate of hypertension among Chinese adults aged ≥ 18 years. Study quality was assessed using a measurement tool developed by the U.S. Agency for Healthcare Research and Quality (AHRQ). Statistical analyses were performed using Stata 18.0. Pooled prevalence, treatment, and control rates were calculated via random-effects models, with meta-regression analysis and subgroup analyses conducted to assess heterogeneity.</p> Results <p>Twenty-seven studies involving 465,805 participants were included. The pooled age-standardized rates (2016–2022) were as follows: hypertension prevalence, 33.1% (95% <i>CI</i>: 29.3%, 37.0%); treatment rate, 32.8% (95% <i>CI</i>: 28.9%, 36.7%); and control rate, 14.9% (95% <i>CI</i>: 11.1%, 18.7%). Geographically, prevalence was highest in Northeast China (47.3%) and lowest in the West (33.3%), while the control rate showed an inverse pattern (West: 19.6%; Northeast: 12.6%) (both <i>p</i> &lt; 0.001). Compared with rural residents, urban residents had a higher treatment rate (49.2% vs. 38.1%, <i>p</i> = 0.008). All three rates increased with age, reaching 59.4%, 42.9%, and 16.8% for prevalence, treatment, and control rates, respectively, in adults aged ≥ 60 years. Men had a higher prevalence than women (39.5% vs. 33.7%, <i>p</i> = 0.038), whereas women had a higher treatment rate (47.4% vs. 41.1%, <i>p</i> = 0.011).</p> Conclusion <p>Hypertension remains a major public health challenge in China. It is essential not only to improve hypertension prevention strategies but also to optimize hypertension control measures while accounting for regional variations and age-related differences.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence and treatment and control rates of hypertension among Chinese adults from 2016 to 2022: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月2日

查看全文
  • Dong-Yue Qi,
  • Xin He,
  • Xiao-Guang Qu,
  • Pu Xu,
  • Hong Chao,
  • Hai-Feng Xue

摘要

Background

Hypertension is a leading cause of cardiovascular and cerebrovascular disease-related morbidity and mortality. This study aimed to investigate the prevalence, treatment rate and control rate of hypertension among Chinese adults from 2019 to the present through a meta-analysis, providing evidence for the development of strategies and measures for hypertension prevention and control at the national level.

Methods

We systematically searched PubMed, Embase, The Cochrane Library, CNKI, Wanfang and VIP to identify cross-sectional studies published from 2019 onwards that reported the prevalence, treatment rate and control rate of hypertension among Chinese adults aged ≥ 18 years. Study quality was assessed using a measurement tool developed by the U.S. Agency for Healthcare Research and Quality (AHRQ). Statistical analyses were performed using Stata 18.0. Pooled prevalence, treatment, and control rates were calculated via random-effects models, with meta-regression analysis and subgroup analyses conducted to assess heterogeneity.

Results

Twenty-seven studies involving 465,805 participants were included. The pooled age-standardized rates (2016–2022) were as follows: hypertension prevalence, 33.1% (95% CI: 29.3%, 37.0%); treatment rate, 32.8% (95% CI: 28.9%, 36.7%); and control rate, 14.9% (95% CI: 11.1%, 18.7%). Geographically, prevalence was highest in Northeast China (47.3%) and lowest in the West (33.3%), while the control rate showed an inverse pattern (West: 19.6%; Northeast: 12.6%) (both p < 0.001). Compared with rural residents, urban residents had a higher treatment rate (49.2% vs. 38.1%, p = 0.008). All three rates increased with age, reaching 59.4%, 42.9%, and 16.8% for prevalence, treatment, and control rates, respectively, in adults aged ≥ 60 years. Men had a higher prevalence than women (39.5% vs. 33.7%, p = 0.038), whereas women had a higher treatment rate (47.4% vs. 41.1%, p = 0.011).

Conclusion

Hypertension remains a major public health challenge in China. It is essential not only to improve hypertension prevention strategies but also to optimize hypertension control measures while accounting for regional variations and age-related differences.